Globus Medical to Acquire Nevro Corp. to Expand Treatment Options for Patients
AUDUBON, Pa. and REDWOOD CITY, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Globus Medical (NYSE: GMED), a leading musculoskeletal solutions company, and Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced they have entered into a definitive agreement for Globus Medical to acquire all shares of Nevro in an all-cash transaction. Under the terms of the agreement, which was unanimously approved by the boards of directors of both companies, Globus Medical will acquire all shares of Nevro for $5.85 per share. The transaction represents a total equity value of approximately $250 million.
'This transaction furthers our mission to become the preeminent musculoskeletal technology company in the world by enabling us to expand into new markets for future growth, while gaining access to world-class, differentiated technologies that can provide significant benefit in neuromodulation, enabling technologies, and future implant solutions. We believe our size and operational capabilities will accelerate market penetration of Nevro's technology and bring much needed and clinically superior relief to patients suffering from chronic pain,' said Dan Scavilla, President and CEO of Globus Medical. 'In addition, our scale and operational discipline will allow us to optimize Nevro's financial performance to drive enhanced profitability and create long-term value moving ahead.'
'We are thrilled to join Globus Medical as this will allow us to reach more patients globally with clinically proven, innovative products that significantly reduce the burden of chronic pain,' said Kevin Thornal, Nevro's CEO and President. 'Through Globus Medical's capabilities, global infrastructure and other resources, we will be better positioned to achieve our full potential to become a broader and more diversified leader in the pain management space."
Transaction Terms
The $5.85 per share consideration represents a 27% premium to the 90-day volume-weighted average price (VWAP) of $4.61, a 38% premium to the 30-day VWAP of $4.23, and a 17% premium to Nevro's closing market price on February 5, 2025. The transaction is expected to close late in the second quarter of 2025, subject to the approval of Nevro's shareholders, regulatory approval, and other customary closing conditions.On January 8, 2025, Globus Medical announced preliminary 2024 net sales of $2.52 billion, an increase of 60.6% over prior year on an as-reported basis; and
On January 13, 2025, Nevro announced preliminary 2024 worldwide revenue of $408 million to $409 million.On a stand-alone basis, Globus Medical reaffirms guidance for 2025 net sales of $2.66 billion to $2.69 billion and fully diluted non-GAAP earnings per share range between $3.40 to $3.50; and
Following the consummation of the transaction and assuming the transaction closes late in the second quarter 2025, Globus Medical anticipates 2025 net sales of $2.80 billion to $2.90 billion and fully diluted non-GAAP earnings per share range between $3.10 to $3.40.
Globus Medical expects the Nevro acquisition to be accretive to its earnings in the second year of operation.Globus Medical expects to report full financial results for 2024 and provide its updated financial outlook for 2025 during its scheduled earnings announcement on February 20, 2025.
Nevro expects to report its full-year 2024 financial results on March 4, 2025. In light of the pending transaction with Globus Medical, Nevro will not hold an earnings conference call and webcast or provide 2025 financial guidance when it reports its 2024 financial results.
Financial and Legal AdvisorsGlobus Medical's financial advisor is Morgan Stanley & Co. LLC and Wyrick Robbins Yates & Ponton LLP is serving as legal advisor. Nevro's financial advisor is BofA Securities, Inc. and Latham & Watkins LLP is serving as legal advisor.
About Globus Medical, Inc.Based in Audubon, Pennsylvania, Globus Medical, Inc. is a leading global musculoskeletal company dedicated to solving unmet clinical needs and changing lives. We innovate with inspired urgency, provide world-class education and clinical support, and advance care throughout spine, orthopedic trauma, joint reconstruction, biomaterials and enabling technologies. Additional information can be accessed at www.globusmedical.com.
About Nevro Corp.Headquartered in Redwood City, California, Nevro Corp. is a global medical device company focused on delivering comprehensive, life-changing solutions that continue to set the standard for enduring patient outcomes in the treatment of chronic pain. Nevro's comprehensive HFX™ spinal cord stimulation (SCS) platform includes the Senza® SCS system and support services for the treatment of chronic pain of the trunk and limb and painful diabetic neuropathy. Nevro also provides minimally invasive treatment options for patients suffering from chronic sacroiliac joint pain. To learn more about Nevro, visit www.nevro.com.
Additional Information and Where to Find It
This communication may be deemed solicitation material in respect of the proposed transaction. A Nevro special stockholder meeting will be announced to obtain Nevro stockholder approval in connection with the proposed transaction. Nevro expects to file with the SEC a proxy statement and has filed or may file with the SEC other relevant documents in connection with the proposed transaction. Nevro stockholders are urged to read the definitive proxy statement and other relevant materials carefully and in their entirety when they become available because they will contain important information about Nevro and the proposed transaction. Investors may obtain a free copy of these materials (when they are available) and other documents filed by Nevro with the SEC at the SEC's website at www.sec.gov, and at Nevro's website at www.nevro.com.
Participants in the Solicitation
Nevro and its directors, executive officers and certain employees and other persons may be deemed to be participants in soliciting proxies from its stockholders in connection with the proposed transaction. Information regarding Nevro's directors and executive officers is set forth in Nevro's proxy statement on Schedule 14A for its 2024 Annual Meeting of Stockholders, which was filed with the SEC on April 12, 2024, and in Nevro's Current Reports on Form 8-K filed with the SEC. Additional information regarding the persons who may, under the rules of the SEC, be considered to be participants in the solicitation of Nevro's stockholders in connection with the proposed transaction and any direct or indirect interests they may have in the proposed transaction will be set forth in Nevro's definitive proxy statement for its special stockholder meeting to be filed with the SEC in connection with the proposed transaction.
Safe Harbor Statements
All statements included in this press release other than statements of historical fact are forward-looking statements and may be identified by their use of words such as 'believe,' 'may,' 'might,' 'could,' 'will,' 'aim,' 'estimate,' 'continue,' 'anticipate,' 'intend,' 'expect,' 'plan' and other similar terms. These forward-looking statements are based on our current assumptions, expectations and estimates of future events and trends. Forward-looking statements are only predictions and are subject to many risks, uncertainties and other factors that may affect our businesses and operations and could cause actual results to differ materially from those predicted. These risks and uncertainties include, but are not limited to, the risks and costs associated with the integration of the Nevro business, trends in the medical industry and the ability of Globus Medical and Nevro to: (i) successfully integrate and achieve anticipated synergies, (ii) manage our growth, (iii) sustain profitability, (iv) sustain demand for products, (v) compete successfully (including without limitation success in convincing surgeons to use Globus Medical or Nevro products and the ability to attract and retain sales and other personnel, (vi) rapidly develop and introduce new products, (vii) develop and execute successful business strategies, (viii) comply with changes and applicable laws and regulations that are or may become applicable to Globus Medical and/or Nevro, (ix) safeguard our intellectual property, and (x) succeed in defending against legal proceedings in addition to general economic conditions and other risks. For a discussion of these and other risks, uncertainties and other factors that could affect our results, refer to the disclosure of each Globus Medical and Nevro contained in each company's most recent annual report on Form 10-K filed with the U.S. Securities and Exchange Commission, including the sections labeled 'Risk Factors' and 'Cautionary Note Concerning Forward-Looking Statements,' and in each company's Forms 10-Q, Forms 8-K and other filings with the U.S. Securities and Exchange Commission. These documents are available at www.sec.gov. Moreover, each of Globus Medical and Nevro operates in an evolving environment. New risk factors and uncertainties emerge from time to time, and it is not possible for Globus Medical and Nevro to predict all risk factors and uncertainties, nor can we assess the impact of all factors on the Globus Medical business and Nevro business, respectively, or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, readers are cautioned not to place undue reliance on any forward-looking statements. Forward-looking statements contained in this press release speak only as of the date of this press release. Globus Medical and Nevro undertake no obligation to update any forward-looking statements as a result of new information, events or circumstances or other factors arising or coming to our attention after the date hereof.
Contacts:
Investors:Brian KearnsSenior Vice President, Corporate Development and Investor RelationsPhone: (610) 930-1800Email: investors@globusmedical.comwww.globusmedical.com
Media:Moran ChavezSenior Director, Corporate AffairsPhone: (619) 318-7681Email: media@globusmedical.com
Nevro Investor & Media Contact:Angie McCabeVice President, Investor Relations & Corporate CommunicationsPhone: (628) 261-9432Email: angeline.mccabe@nevro.comwww.nevro.comSign in to access your portfolio
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
17 minutes ago
- Yahoo
Recreational Vehicle Maker Thor's European Sales Hit By Dip, Cautions On Macro Outlook
Thor Industries, Inc. (NYSE:THO) shares are trading higher on Wednesday after the company reported third-quarter EPS of $2.53 beating the street consensus of $1.83. Quarterly sales of $2.89 billion, up 3.3% year over year (Y/Y), outpaced the analyst consensus estimate of $2.48 billion. Gross profit margin in the quarter under review expanded by 20 basis points year over year to 15.3%.Adjusted EBITDA increased 7.9% Y/Y to $254.8 million in the quarter. North American Towable Recreational Vehicle (RV) net sales increased 9.1% Y/Y, while North American Motorized RV net sales rose 3.1% Y/Y in the quarter. North American Towable RV net sales benefitted from 5.5% higher unit shipments and a 3.6% increase in net price per unit. Gross profit margin improved 200 basis points to 14.9%, attributed to higher sales, less discounting, better warranty costs, and ongoing savings. North American Motorized RV net sales increased due to a 10.9% rise in unit shipments (partly from promotions), though a 7.8% decrease in net price per unit (due to product mix shift and higher discounting) partially offset this. Gross profit margin fell to 10.5% from 11.1%, primarily owing to increased sales discounting. As of April 30, the order backlog for North American Towable RV stood at $634.3 million (-14.4%) and North American Motorized RV came in at $883.7 million (-4.5%). European RV net sales decreased 5.1% Y/Y for the quarter, led by a 12.2% decrease in unit shipments, which was offset in part by a 7.1% Y/Y increase in the overall net price per unit. European RV net sales fell due to a 12.2% drop in unit shipments, partially offset by a 7.1% increase in net price per unit. The price increase included a 6.8% rise from product mix and pricing changes, plus a 0.3% benefit from foreign currency exchange rates. European RV gross profit margin contracted 130 basis points to 16.2% on increased sales discounting. As of April 30, the order backlog for European RV came in at $1.34 billion (-30.6%). The company exited the quarter with cash and cash equivalents worth $508.3 million, with net inventories worth $1.35 billion. Long-term debt (net) at the end of the quarter stood at $1.01 billion. Todd Woelfer, senior VP and COO, said, 'As we anticipated and messaged at the beginning of our fiscal year, our North American Motorized and European segments have both seen year-over-year declines in gross margin but still achieved resilient results considering the challenging environments facing those segments.' 'While our consolidated margin this quarter was unfavorably impacted by actions we took to deepen our partnerships with key dealers, strategically, deepening these key relationships is vital to our long-term market position and these decisions favorably position THOR for the future as we look ahead,' Thor Industries reaffirmed its FY25 EPS guidance of $3.30 to $4.00 compared to analyst estimates of $3.59. The company also maintained its FY25 sales guidance at $9.00 billion to $9.50 billion versus the analyst estimate of $9.25 billion. Bob Martin, president and CEO, added, 'Our financial guidance assumed a stronger second half of our fiscal year, and our fiscal third quarter performance reflects the value of our strategies in the currently difficult market.' 'We expect the fourth quarter of our fiscal 2025 and the first quarter of our fiscal 2026 to be challenging. The current economic uncertainty has led to downward pressure on consumer confidence and has negatively impacted retail pull-through. We believe that upon the resolution of this uncertainty, we will see improved consumer confidence and the return of a strong retail environment,' he added. Year-to-date, the stock has declined around 11%. The short float for Thor Industries is 18.33%, according to data from Benzinga Pro. Price Action: THO shares are trading higher by 3.44% to $85.25 at last check Wednesday. Read Next:Image by Michael Gordon via Shutterstock UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? THOR INDUSTRIES (THO): Free Stock Analysis Report This article Recreational Vehicle Maker Thor's European Sales Hit By Dip, Cautions On Macro Outlook originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Sign in to access your portfolio
Business Wire
26 minutes ago
- Business Wire
BIS Issues Notice of Intent to Deny Applications for Licenses to
HOUSTON--(BUSINESS WIRE)--Enterprise Products Partners L.P. ('Enterprise') (NYSE: EPD) today announced that yesterday, June 3, 2025, Enterprise received notice from the U.S. Department of Commerce's Bureau of Industry and Security ('BIS') of BIS's intent to deny Emergency Authorization Requests ('EARs') with regard to three proposed cargoes of ethane to China, totaling approximately 2.2 million barrels. Per the Notice, Enterprise has up to twenty days to respond to BIS with any comments or rebuttals with regard to these affected EARs. Unless Enterprise is advised by the 45 th day after the date of the notification, these denials will become final without further notice. As previously disclosed on May 29, 2025 in a Current Report on Form 8-K filed by Enterprise with the U.S. Securities and Exchange Commission, on the afternoon of Friday, May 23, 2025, BIS notified Enterprise of new licensing requirements for exports of 'ethane and butane, saturated, having a purity of 95 percent or more by volume' to China. This new licensing requirement was effective immediately (the licensing requirement for butane was subsequently withdrawn). According to the U.S. Energy Information Administration ('EIA'), total U.S. ethane production in 2024 was approximately 2.8 million barrels per day ('BPD') and total U.S. ethane exports were approximately 492,000 BPD. U.S. ethane exports to China were approximately 227,000 BPD in 2024, representing 8 percent of total U.S. ethane production and 46 percent of total U.S. ethane exports. Enterprise's marine export terminal on the Houston Ship Channel loaded approximately 213,000 BPD of ethane in 2024 of which approximately 40 percent, or 85,000 BPD, were destined to Chinese markets. Ethane exports destined to China from Enterprise's Morgan's Point facility in 2024 represented only 37 percent of total U.S. ethane exports to China for 2024. Currently, Enterprise estimates that total U.S. ethane exports to China has increased to approximately 290,000 BPD in 2025. Company Information and Use of Forward-Looking Statements Enterprise Products Partners L.P. is one of the largest publicly traded partnerships and a leading North American provider of midstream energy services to producers and consumers of natural gas, NGLs, crude oil, refined products and petrochemicals. Services include: natural gas gathering, treating, processing, transportation and storage; NGL transportation, fractionation, storage and marine terminals; crude oil gathering, transportation, storage and marine terminals; petrochemical and refined products transportation, storage and marine terminals; and a marine transportation business that operates on key U.S. inland and intracoastal waterway systems. The partnership's assets currently include more than 50,000 miles of pipelines; over 300 million barrels of storage capacity for NGLs, crude oil, petrochemicals and refined products; and 14 billion cubic feet of natural gas storage capacity. This press release includes 'forward-looking statements' as defined by the Securities and Exchange Commission. All statements, other than statements of historical fact, included herein that address activities, events, developments or transactions that Enterprise and its general partner expect, believe or anticipate will or may occur in the future are forward-looking statements. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from expectations, including required approvals by regulatory agencies, the possibility that the anticipated benefits from such activities, events, developments or transactions cannot be fully realized, the possibility that costs or difficulties related thereto will be greater than expected, the impact of competition, and other risk factors included in Enterprise's reports filed with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates. Except as required by law, Enterprise does not intend to update or revise its forward-looking statements, whether as a result of new information, future events or otherwise.
Yahoo
30 minutes ago
- Yahoo
GCC Structural Steel Fabrication Industry Report 2025-2030: How Mega-Projects and Urbanization Are Driving Growth
The GCC structural steel fabrication market is growing due to infrastructure projects and urbanization in Saudi Arabia, UAE, and Qatar. Prefabrication and smart technologies boost demand, aligning with economic diversification goals, despite challenges like fluctuating raw material prices and reliance on imports. GCC Structural Steel Fabrication Market Dublin, June 04, 2025 (GLOBE NEWSWIRE) -- The "GCC Structural Steel Fabrication Market, By Country, Competition, Forecast & Opportunities, 2020-2030F" has been added to offering. The GCC Structural Steel Fabrication Market was valued at USD 10.11 Billion in 2024, and is expected to reach USD 13.79 Billion by 2030, rising at a CAGR of 5.15% Structural steel fabrication, essential for producing components used in high-load-bearing structures, is seeing robust demand in the GCC due to extensive infrastructure developments. The region's ongoing urbanization, coupled with mega-projects in Saudi Arabia, UAE, and Qatar, is boosting the need for prefabricated steel components. Structural steel's strength, adaptability, and eco-friendliness make it a favored material in commercial, industrial, and residential construction. The shift toward prefabrication and smart technologies in construction further supports the market's growth, aligning with the GCC's economic diversification and sustainability goals. Robust Growth in the Construction Sector The construction sector across GCC countries is a key catalyst for the structural steel fabrication market, fueled by large-scale investments in infrastructure as part of economic diversification efforts. Major initiatives such as Saudi Vision 2030 and infrastructure-driven events like Dubai Expo and the FIFA World Cup have spurred the demand for steel structures in residential, commercial, and industrial developments. Projects like NEOM, Qiddiya, and the Red Sea Development are examples where structural steel plays a pivotal role in modern, sustainable construction. The material's inherent benefits - high strength, design flexibility, and recyclability - make it indispensable for innovative architecture and complex engineering requirements, driving continued demand throughout the region. Fluctuating Raw Material Prices The volatility in steel prices presents a significant hurdle for the structural steel fabrication market in the GCC. Limited domestic steel production necessitates imports, exposing the market to global supply chain disruptions, tariffs, and currency fluctuations. This dependency introduces financial unpredictability for fabrication firms, especially under fixed-price project contracts. Spikes in material costs can delay timelines, compress margins, and complicate budgeting. While companies are adopting cost-control strategies like supply diversification and advanced procurement tools, raw material cost instability remains a persistent constraint, particularly affecting SMEs and long-term project planning. Rising Adoption of Advanced Technologies Advanced technologies are transforming the structural steel fabrication landscape in the GCC. Firms are integrating CAD, CAM, and BIM systems to enhance design accuracy and coordination, minimizing rework and accelerating timelines. Automation - through robotic welding, CNC machining, and laser cutting - is boosting production efficiency and reducing reliance on manual labor, which is increasingly expensive in the region. IoT integration for process monitoring and predictive maintenance is also gaining traction, contributing to quality assurance and operational reliability. These innovations align with regional development visions like Saudi Vision 2030 and the UAE's Industry 4.0 agenda, signaling a shift toward smarter, more efficient steel fabrication processes. Key Attributes: Report Attribute Details No. of Pages 125 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $10.11 Billion Forecasted Market Value (USD) by 2030 $13.79 Billion Compound Annual Growth Rate 5.1% Regions Covered Middle East Report Scope Key Market Players ArcelorMittal Tata Steel Limited Baosteel Group Corporation Nippon Steel Corporation JFE Steel Corporation China Steel Corporation TENARIS Steel Dynamics, Inc GCC Structural Steel Fabrication Market, By Service: Metal Welding Metal Forming Shearing Metal Cutting Metal Shearing Metal Stamping Machining Metal Rolling GCC Structural Steel Fabrication Market, By Application: Construction Automotive Manufacturing Energy & Power Electronics Defense & Aerospace GCC Structural Steel Fabrication Market, By Country: Bahrain Kuwait Oman Qatar Saudi Arabia United Arab Emirates For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment GCC Structural Steel Fabrication Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
